A Phase I/IIa clinical proof-of-concept trial of RTX-134 for the treatment of phenylketonuria
Phase of Trial: Phase I/II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs RTX-134 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; Proof of concept
- Sponsors Rubius Therapeutics
- 07 Jan 2019 According to a Rubius Therapeutics media release, initial clinical data from part1 of this study is expected in the second half of 2019.
- 14 Sep 2018 New trial record
- 31 Aug 2018 According to a Rubius Therapeutics media release, the company intends to file an IND application for RTX-134 for Phenylketonuria in the first quarter of 2019.